Skip to main content
spacbrain

biote

Closed (deSPAC)

Health Care · bioidentical hormone optimization therapy

What it is
Biote is a woman-led company operating a high growth, differentiated medical practice-building business within the hormone optimization space
What it’s doing now
Merging with Haymaker Acquisition Corp. III (BTMD) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Biote is a woman-led company operating a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, and successfully operate a hormone optimization center to treat patients appropriate for therapy. Biote trains practitioners how to identify and treat early indicators of hormone-related aging conditions.

Source: S-4/A, accession 0001193125-23-151250

What the company says about itself

Web research — not audited
What our web check found

[WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Following the transaction, the combined company was renamed biote Corp., beginning on May 27, 2022." [https://ir.biote.com/news-releases/news-release-details/biote-debuts-publicly-traded-company-focused-transforming/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The business combination is expected to be completed in the first half of 2022" [https://biote.com/es/press-releases/biote-to-be-listed-on-nasdaq-through-a-business-combination-with-haymaker-acquisition-corp-iii] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Combination is anticipated to take place on or about May 26" [https://www.globenewswire.com/news-release/2022/05/24/2449816/0/en/haymaker-acquisition-corp-iii-announces-stockholder-approval-of-business-combination-with-biote.html] [WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Following the transaction, the combined company was renamed biote Corp., beginning on May 27, 2022." [https://ir.biote.com/news-releases/news-release-details/biote-debuts-publicly-traded-company-focused-transforming/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The business combination is expected to be completed in the first half of 2022" [https://biote.com/es/press-releases/biote-to-be-listed-on-nasdaq-through-a-business-combination-with-haymaker-acquisition-corp-iii] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Combination is anticipated to take place on or about May 26" [https://www.globenewswire.com/news-release/2022/05/24/2449816/0/en/haymaker-acquisition-corp-iii-announces-stockholder-approval-of-business-combination-with-biote.html]

Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

biote is merging with Haymaker Acquisition Corp. III (BTMD) currently marked Closed (deSPAC).

Headline equity value—

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is biote going public?

biote has an approved merger with the SPAC Haymaker Acquisition Corp. III (BTMD). Deal status: Closed (deSPAC).

Does biote have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals